- Home
- CSR vs TNDM Comparison
CSR vs TNDM Comparison
Compare CSR & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSR
- TNDM
- Stock Information
- Founded
- CSR 1970
- TNDM 2006
- Country
- CSR United States
- TNDM United States
- Employees
- CSR N/A
- TNDM N/A
- Industry
- CSR Real Estate Investment Trusts
- TNDM Medical/Dental Instruments
- Sector
- CSR Real Estate
- TNDM Health Care
- Exchange
- CSR Nasdaq
- TNDM Nasdaq
- Market Cap
- CSR 1.0B
- TNDM 1.1B
- IPO Year
- CSR N/A
- TNDM 2013
- Fundamental
- Price
- CSR $57.27
- TNDM $12.63
- Analyst Decision
- CSR Buy
- TNDM Buy
- Analyst Count
- CSR 7
- TNDM 16
- Target Price
- CSR $70.00
- TNDM $23.50
- AVG Volume (30 Days)
- CSR 93.7K
- TNDM 1.8M
- Earning Date
- CSR 10-27-2025
- TNDM 11-05-2025
- Dividend Yield
- CSR 5.35%
- TNDM N/A
- EPS Growth
- CSR N/A
- TNDM N/A
- EPS
- CSR N/A
- TNDM N/A
- Revenue
- CSR $267,076,000.00
- TNDM $1,001,719,000.00
- Revenue This Year
- CSR $5.37
- TNDM $8.27
- Revenue Next Year
- CSR $3.01
- TNDM $9.72
- P/E Ratio
- CSR N/A
- TNDM N/A
- Revenue Growth
- CSR 3.44
- TNDM 25.84
- 52 Week Low
- CSR $52.76
- TNDM $9.98
- 52 Week High
- CSR $75.92
- TNDM $47.60
- Technical
- Relative Strength Index (RSI)
- CSR 46.10
- TNDM 49.72
- Support Level
- CSR $57.57
- TNDM $12.05
- Resistance Level
- CSR $60.83
- TNDM $13.18
- Average True Range (ATR)
- CSR 1.36
- TNDM 0.62
- MACD
- CSR -0.17
- TNDM 0.17
- Stochastic Oscillator
- CSR 5.21
- TNDM 62.84
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.
About TNDM Tandem Diabetes Care Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.